Peptidic thrombin inhibitors

Details Peptidic thrombin inhibitors Peptidic thrombin inhibitors

2008-09-09

2008-09-09

Kosar, Andrew D. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S300000, C530S329000, C530S333000

Reexamination Certificate

active

10542519

ABSTRACT:
The invention relates to biologically active molecules, which interact with and inhibit thrombin. The invention particularly relates to molecules of general formula (I): Y1—(NH—X1—CO)—(NH—X2—C═O)—(NH—X3—C═O)—(NH—X.sup.4—C═O)—(NH—X6—C═O) (NH—X6—C═O)—Y2, wherein the compound can be used for thrombin inhibition, inhibition of fibrin formation, and/or for the inhibition of the formation of a clot. Compounds disclosed herein can also be used for treatingm, diagnosing, and prophylaxis of thrombotic disorders.

REFERENCES:
patent: 3826794 (1974-07-01), Flouret
patent: 4654302 (1987-03-01), Fritz et al.
patent: 5433940 (1995-07-01), Maraganore et al.
patent: 7081447 (2006-07-01), Thurk
patent: 168342 (1986-01-01), None
patent: 171024 (1986-02-01), None
patent: 200655 (1986-11-01), None
patent: WO-03/022873 (2003-03-01), None
R.J. Bastin, et al. Org. Proc. Res. Develop. (2000) 4, pp. 427-435.
English equivalent for claims of WO 03/022873 A1 (pp. 49-73).
Claeson, G.; “Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System”; Blood Coagulation & Fibrinolysis, Rapid Communications, Oxford, GB, vol. 5, 1994, pp. 411-436.
Kamphausen, Stefan, et al.; “Genetic algorithm for the design of molecules with desired properties”; Journal of Computer-Aided Molecular Design, vol. 16, No. 8-9, 2002, pp. 551-567.
Stone, Stuart R. & Hofsteenge, Jan, “Kinetics of the Inhibition of Thrombin by Hirudin.” Biochemistry, 1986, vol. 25, pp. 4622-4628.
Markwardt, F., et al., “Pharmacological Studies on the Antithrombotic Action of Hirudin in Experimental Animals.” From the Institute of Pharmacology and Toxicology, Medical Acadamy Erfurt, Erfurt, G.D.R., 1982, pp. 226-229.
Harvey, R.P., et al. “Cloning and Expression of a cDNA Coding for the Anticoagulant Hirudin From the Bloodsucking Leech,Hirudo Medicinalis.” Proc. Natl. Acad. Sci., Feb. 1986, vol. 83, pp. 1084-1088.
Wirsching, Frank, et al. “Display of Functional Thrombin Inhibitor Hirudin on the Surface of Phage M13.” Gene 204, 1997, p. 177-184.
Bergmann, Cornelia, et al. “Chemical Synthesis and Expression of a Gene Coding for Hirudin, the Thrombin-Specific Inhibitor From the LeechHirudo Medicinalis.” Biol. Chem. Hoppe-Seyler, Aug. 1968, vol. 367, p. 731-740.
Shuman, Robert T., et al. “Highly Selective Tripeptide Thrombin Inhibitors.” Journal of Med. Chem., 1993, vol. 36, p. 314-319.
Blomback, B., et al. “Synthetic Peptides with Anticoagulant and Vasodilating Activity.” Scan. J. Clin. Lab. Invest. Suppl., 1969, vol. 107, p. 59-64.
Bajusz, S., et al. “Inhibition of Thrombin and Trypsin by Tripeptide Aldehydes.” Int. J. Peptide Protein Res., 1978, vol. 12, p. 217-221.
Kettner & Shaw, “D-PHE-PRO-ARGCH2C1-A Selective Affinity Label for Thrombin.” Thrombosis Research, 1979, vol. 14, p. 969-973.

Affiliated with

Also associated with

Rating

Peptidic thrombin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptidic thrombin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidic thrombin inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3943274